Healthcare systems should fund sildenafil

Although sildenafil has been shown to be an effective treatment for erectile dysfunction, governments are concerned about its affordability for healthcare systems. Stolk conducted a cost utility analysis comparing sildenafil with conventional injection treatment (p 1165). Erectile function was perceived by the general public to limit quality of life considerably, and the quality of life gained by treatment was estimated at 0.11 QALY. The cost per QALY was £3639 in the first year, and lower in subsequent years. The authors suggest that the cost utility ratio supports funding of sildenafil, although frequency of use should be limited.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Cost utility analysis of sildenafil compared with papaverine-phentolamine injections

Elly A Stolk, Jan J V Busschbach, Max Caffa, Eric J H Meuleman, and Frans F H Rutten
BMJ 2000 320: 1165. [Abstract] [Full Text] [PDF]